In this study, 140 heavy drinking young adults (aged 18-25) will be provided with brief
counseling and either naltrexone, a medication that is FDA-approved for the treatment of
alcohol dependence, or placebo over the course of 8 weeks. A novel strategy will be used for
administering low-dose naltrexone, in which daily dosing will be combined with targeted
dosing in anticipation of high-risk situations. The main hypotheses are that daily + targeted
naltrexone will result in greater reductions in frequency of heavy and any drinking compared
with daily + targeted placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)